PDCD1 and neoplasm: In mouse tumor transplant models, treatment with TIGIT-blocking antibodies alone did not decrease tumor burden, but treatment with TIGIT blocking antibodies in combination with anti-PD-L1 or anti-PD-1 treatment brought about a robust anti-tumor response [76].